

Haematologica
HAEMATOL/2017/164632
Version 4

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Tania Díaz, Vanina Rodríguez, Ester Lozano, Mari-Pau Mena, Marcos Calderón, Laura Rosiñol, Antonio Martínez, Natalia Tovar, Patricia Pérez-Galán, Joan Bladé, Gaël Roué, and Carlos Fernández de Larrea

Disclosures: None

Contributions: T.D. designed and performed the research, analyzed the data and wrote the manuscript; V.R., E.L, M.P.M. and M.C. performed experiments and analyzed results; L.R., A.M. and N.T. selected cases and analyzed the clinical data; P.P. analyzed the data and wrote the manuscript; J.B., G.R. and C.F.L. designed and supervised the research and wrote the paper. All authors have read and approved the final version of the manuscript and agreed with the decision to submit